Advertisement
BMY vs NVS
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Novartis (NVS) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has demonstrated relative outperformance in recent market activity, supported by oncology pipeline advancements and upcoming quarterly results.
- Novartis (NVS) maintains a diversified portfolio across oncology, cardiovascular, and other therapeutic areas, with steady positioning in global pharmaceutical markets.
- Both companies operate in the healthcare sector, facing similar regulatory and competitive dynamics, though BMY has shown more pronounced recent momentum tied to specific drug approvals.
- Dividend yields and earnings expectations provide key points of contrast, with BMY offering a higher trailing yield amid analyst focus on its growth drivers.
- Market sentiment for both reflects broader pharma trends, including pipeline updates and macroeconomic influences on healthcare spending.
- Relative performance highlights trade-offs in stability versus catalyst-driven moves in the current environment.
Introduction
This comparison examines Bristol-Myers Squibb (BMY) and Novartis (NVS), two established pharmaceutical companies with significant exposure to oncology and other high-value therapeutic categories. The analysis focuses on recent performance trends, business fundamentals, and market positioning to assist investors and traders evaluating relative opportunities within the healthcare sector. Those seeking to understand how established drugmakers navigate pipeline developments, regulatory milestones, and sector-wide pressures may find this overview particularly relevant for portfolio construction or tactical allocation decisions.
BMY Overview and Recent Performance
Bristol-Myers Squibb is a global biopharmaceutical company focused on oncology, hematology, immunology, and cardiovascular treatments. In recent weeks, BMY shares have exhibited resilience, closing near $60.74 and posting gains even as broader indexes declined. Positive sentiment has been influenced by advancements in its oncology portfolio, including FDA acceptance of new drug applications and ongoing clinical trial progress. The company is scheduled to report second-quarter results on July 30, with analysts projecting modest EPS growth. A trailing dividend yield of approximately 4.15% has also supported investor interest amid a stable payout history.
NVS Overview and Recent Performance
Novartis is a multinational pharmaceutical company with a broad portfolio spanning oncology, cardiovascular, neuroscience, and ophthalmology products. In recent market activity, NVS has maintained a more measured performance profile consistent with its diversified revenue base and global operations. The stock has reflected steady institutional interest, supported by ongoing pipeline updates and established product franchises. Broader sector dynamics, including regulatory reviews and competitive pressures, have shaped sentiment, though specific recent catalysts have been less pronounced compared to peers with concentrated oncology exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, but only the best and most suitable for current market conditions earn placement in this section. Available bots feature a wide range of trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical win rates and returns varying across configurations. This resource allows users to explore automated approaches tailored to equities like those discussed here. Explore the options at Trending AI Robots.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) and Novartis (NVS) both derive substantial revenue from innovative medicines, yet differ in portfolio concentration and geographic emphasis. BMY leans more heavily toward oncology and immunology, creating potential for sharper reactions to clinical or regulatory news, while NVS benefits from greater diversification that can dampen volatility. Recent momentum favors BMY due to visible pipeline progress, whereas NVS offers relative stability in earnings visibility. Risk factors for both include patent expirations, pricing pressures, and clinical trial outcomes, though sector exposure remains aligned within healthcare. Market sentiment currently tilts toward catalyst sensitivity for BMY versus consistent dividend support and global scale for NVS.
Tickeron AI Verdict
Based on observable factors such as recent trend consistency and pipeline-related catalysts, Tickeron’s AI models indicate a probabilistic preference for Bristol-Myers Squibb (BMY) in the near term. This assessment reflects stronger relative momentum and upcoming earnings visibility compared to the more stable but less dynamic profile of Novartis (NVS). The view remains conditional on continued execution and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and NVS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 4 green FA rating(s).
- BMY’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 7 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 3 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +2.22% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.81% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
NVS is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | NVS | BMY / NVS | |
| Capitalization | 127B | 295B | 43% |
| EBITDA | 15B | 22.4B | 67% |
| Gain YTD | 18.999 | 15.830 | 120% |
| P/E Ratio | 17.39 | 23.42 | 74% |
| Revenue | 48.5B | 56.6B | 86% |
| Total Cash | N/A | 6.98B | - |
| Total Debt | 46.4B | 47B | 99% |
BMY | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 6 | |
SMR RATING 1..100 | 25 | 28 | |
PRICE GROWTH RATING 1..100 | 14 | 46 | |
P/E GROWTH RATING 1..100 | 54 | 23 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as NVS (8). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (83). This means that NVS’s stock grew significantly faster than BMY’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as NVS (28). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.
BMY's Price Growth Rating (14) in the Pharmaceuticals Major industry is in the same range as NVS (46). This means that BMY’s stock grew similarly to NVS’s over the last 12 months.
NVS's P/E Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as BMY (54). This means that NVS’s stock grew similarly to BMY’s over the last 12 months.
| BMY | NVS | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 56% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 54% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 59% | 3 days ago 40% |
| TrendWeek ODDS (%) | 3 days ago 53% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 50% |
| Advances ODDS (%) | 3 days ago 54% | 10 days ago 52% |
| Declines ODDS (%) | 26 days ago 55% | 13 days ago 46% |
| BollingerBands ODDS (%) | 3 days ago 56% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 67% | 3 days ago 48% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.